Leqembi (lecanemab) and Kisunla (donanemab) are proven to slow cognitive and functional decline by 27 and 35%, respectively.

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

They are now facing the first direct competition to Leqembi from Eli Lilly's Kisunla (donanemab), which has been approved with a fixed duration of treatment until amyloid plaques in the brain resolve.

New treatments can slow the disease’s progress, which is why the Alzheimer’s Association is leveraging its celebrity partners ...

help Eisai and Biogen differentiate Leqembi from Eli Lilly's recently approved rival Kisunla (donanemab), and potentially speed up take-up of their drug, which remains fairly sluggish. Lilly has ...

New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study ...

More than a decade after hosting clinical trials for two medications now commonly used to slow the progression of Alzheimer’s ...

Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...